Join BJS Academy
BJS Academy>Randomized clinical ...>21 Gene assay to inf...
Normal View Dyslexic View

21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.

1 January 2022
Randomized clinical trials Breast
Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF et al.
N Engl J Med 2021; 385: 2336-2347

The study included 5083 women with hormone receptor positive, HER 2 negative breast cancer with 1-3 positive axillary nodes and a recurrence score above 25. They all received endocrine therapy, and were randomized to additional chemotherapy. Five year overall survival rates were not improved with chemotherapy: 91.3 versus 91.9 percent, but disease-free survival was better in premenopausal women.

Comment: A large and complex trial that helps inform how to mange women with node positive breast cancer.

BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
rct254
Randomized clinical trials
Randomized clinical trials
Breast
21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.
Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF et al.N Engl J Med 2021; 385: 2336-2347
01012022
The study included 5083 women with hormone receptor positive, HER 2 negative breast cancer with 1-3 positive axillary nodes and a recurrence score above 25. They all received endocrine therapy, and were randomized to additional chemotherapy. Five year overall survival rates were not improved with chemotherapy: 91.3 versus 91.9 percent, but disease-free survival was better in premenopausal women.
Comment: A large and complex trial that helps inform how to mange women with node positive breast cancer.
Published on: 1 January 2022
Article ID: rct254

Related articles

Aspirin vs placebo as adjuvant therapy for breast cancer. The Alliance A011502 randomized trial.

Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM et al.

16 August 2024

Event-free survival with pembrolizumab in early triple-negative breast cancer.

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S et al, for the KEYNOTE-522 Investigators.
N Engl J Med 2022; 386: 556-567.

1 March 2022

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).

17 May 2022
  • Normal view
  • Dyslexic view
Copied!